Autopsy report · NCT02323126

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

“Sponsor decision due to low patient recruitment caused by the change in the treatment landscape of NSCLC.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 6 years before it stopped.
• 64 participants enrolled.
• Results were posted on the registry 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Non Small Cell Lung Cancer

Interventions

EGF816; INC280; Nivolumab

Participants

64

Sites

13

Countries

Australia, France, Germany, Italy, Singapore, Spain, Switzerland, United States

Trials that died the same way

• A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
  “Sponsor Decision; strategic - based on changing treatment landscape” (69% match in meaning)
• Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
  “Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative therapy and clinician's choice to put patient on immunotherapy outside of trial setting.” (67% match in meaning)
• Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
  “Sponsor decision following clinical hold” (62% match in meaning)
• A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
  “Sponsor's clinical development strategy adjustment” (62% match in meaning)
• Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
  “Lack of treatment, sponsor decision.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.